CANbridge Pharmaceuticals Data on  CAN106, to be Presented at Two Conferences

Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

CANbridge Pharmaceuticals Presented at the Jefferies Asia Forum

CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2   Trial for the Treatment of Gaucher Disease in China

First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

  -  China Study is Part of Global EMBARK Study

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

CANbridge Appoints Industry Leader Edward Hu to the Board

CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress